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Iscador Qu inhibits doxorubicin-
induced senescence of MCF7 cells
Tatjana Srdic-Rajic1, Juan F. Santibañez2,3, Ksenija Kanjer1, Nevena Tisma-Miletic1, Milena 
Cavic1, Daniel Galun4,5, Marko Jevric6, Nevena Kardum7, Aleksandra Konic-Ristic7 &  
Tamara Zoranovic  1,8
Chemotherapy in patients with inoperable or advanced breast cancer inevitably results in low-dose 
exposure of tumor-cell subset and senescence. Metabolically active senescent cells secrete multiple 
tumor promoting factors making their elimination a therapeutic priority. Viscum album is one of the 
most widely used alternative anti-cancer medicines facilitating chemotherapy tolerance of breast 
cancer patients. The aim of this study was to model and investigate how Viscum album extracts execute 
additive anti-tumor activity with low-dose Dox using ER + MCF7 breast cancer cells. We report that 
cotreatment of MCF7 with Viscum album and Dox abrogates G2/M cycle arrest replacing senescence 
with intrinsic apoptotic program. Mechanistically, this switch was associated with down-regulation of 
p21, p53/p73 as well as Erk1/2 and p38 activation. Our findings, therefore, identify a novel mechanistic 
axis of additive antitumor activity of Viscum album and low dose-Dox. In conclusion, ER + breast cancer 
patients may benefit from addition of Viscum album to low-dose Dox chemotherapy due to suppression 
of cancer cell senescence and induction of apoptosis.
Despite significant progress made in early diagnosis and treatment, breast cancer remains the most frequent can-
cer amongst women and the second most common cancer type in the world1, 2.
Hormone receptor positive breast cancers represent two thirds of all breast cancers diagnosed today3, 4. 
Despite effective targeted treatment strategies4 the use of chemotherapeutics is indicated for patients with pri-
mary inoperable and advanced ER/PR positive breast cancers unresponsive to first line therapy4. Doxorubicin 
(Dox), a naturally occurring anthracycline antibiotic5 has long been used as a chemotherapeutic component in 
breast cancer patient treatment6–8.
Antitumor activity of Dox has been assigned to induction of DNA damage and ROS production9. The amount 
of genotoxic stress and total ROS production dictates possible outcomes such as cell death or G1 and/or G2 cell 
cycle arrest and senescence10–12. Senescence induced by chemotherapeutics (therapy induced senescence, TIS) 
has been well studied in vitro and, more recently, detected in breast tumors of patients undergoing pre-operative 
neoadjuvant chemotherapy13. Though TIS has been long considered a desirable therapeutic outcome and a prom-
ising strategy in overcoming therapy resistance13–15, a growing body of work has indicated that TIS cells may 
alter response to chemotherapy16, escape cell cycle arrest17, 18 and promote tumor growth19 (reviewed in refs20,21). 
Most of these detrimental effects have been attributed to both autocrine and paracrine activity of senescent cell 
secretome designated as Senescence Associated Secretory Phenotype or SASP.
SASP components contributing to relapse and aggressive cancer occurrence22 include: interleukins 6 and 8 
(IL-6, IL-8)23; amphiregulin (AREG) and growth-related oncogene (GRO) α24, 25, VEGF26, 27 or matrix metallo-
proteinases (MMPs)25, 28, 29. SASP has recently been linked to immune surveillance of damaged normal and tumor 
cells30–32. During acute normal and tumor tissue injury, one of the key SASP functions is to attract immune cells 
facilitating clearance of damaged senescent cells33, 34. However, under conditions of persistent tissue injury, dam-
aged normal and tumor cells undergo immunoediting escaping immune surveillance35, an effect recently linked 
to SASP secretome36.
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Therefore, compelling evidence indicates that non-cell autonomous action of SASP secretome could drive can-
cer relapse making eradication of therapy induced senescent cells a priority for researchers today. Complementary 
Alternative Medicines have long been used in oncotherapy both as therapeutic efficacy enhancers whilst facili-
tating tolerance of its side effects37–44. Phytochemical preparations of mistletoe, including aqueous extracts, are 
among the most frequently prescribed complementary and alternative therapies for cancer in Europe45. Despite 
well documented research and clinical studies supporting beneficial effects of Mistletoe as a complementary 
cancer medicine37–44, the most challenging obstacle towards its definitive inclusion in oncotherapy is a lack of 
preparation with standardized anti-tumor activity. While Viscum Album Extracts (VAE) exhibit potent tumor 
toxicity where several isolated extract compounds, such as Mistletoe Lectins (MLs), have been demonstrated to 
have strong apoptosis-inducing effects46–48. ML-induced apoptosis is primarily triggered by PI3K/Akt-, MAPK-, 
TLR-signalling resulting in the activation of caspases49–51. Its cytotoxic and anti-metastatic effect has been demon-
strated in different solid tumours and leukaemia cell lines in vitro and in vivo52–55. MLs also display cytotoxic 
effects on multidrug-resistant cancer cells (e.g. MDR + colon cancer cells56 and enhance cytotoxicity of anticancer 
drugs57, 58.
Furthermore, VAEs seem to interfere with tumour angiogenesis59, 60. Injected into tumour-bearing animals, 
VAEs display growth-inhibiting and tumor reducing effects61, 62. Iscador Qu 5 mg Spezial represents Mistletoe 
aqueous extract suitable for subcutaneous injections with standardized dry substance, viscotoxin and mistletoe 
lectin content63, 64. Antitumor-activity of Mistletoe extracts has been shown to vary depending on both har-
vest season and host plant species65 allowing for designations such as Qu, M or P identifying Mistletoe hosts as 
Quercus (oak), Malus (Apple) or Pinus (Pine) respectively.
We have previously shown that Viscum album/aqueous extract (VAE) increases anti-leukemic effectiveness of 
doxorubicin by preventing G2/M arrest and inducing apoptosis66. The aim of this study was to investigate whether 
Viscum album preparation (Iscador Qu) potentiates Dox toxicity at sub-therapeutic concentrations in MCF7 
ER + breast cancer cells as well as its mechanism of action.
Results
Isc Qu treatment of MCF7 cells abrogates low-dose Dox induced G2/M arrest. Baring in mind 
that low-dose chemotherapy induces cell cycle arrest and senescence, we wanted to ask the question whether 
Mistletoe extract (Isc Qu) anti-tumor activity targets this cell population.
In a series of 48 and 72 h treatments of MCF7 cells with increasing Isc Qu and Dox concentrations (Fig. S1A 
left and right tables, respectively), we have observed the strongest synergistic cytotoxicity after 72 h treatment 
with 50 nM Dox and 85 ug/mL Isc Qu (Fig. S1A). Furthermore, 72 h treatment of MCF7 cells with 50 nM Dox had 
the lowest impact on cell viability (Fig. 1A, top left) while potently inducing G2/M arrest (Fig. 1B). MTT assay67, 68  
results after 72 h treatment of MCF7 cells with a range of Isc Qu concentrations revealed that IC50 value for 
Iscador Qu was 43.4 µg/mL (Fig. 1A, top right). Interestingly, 72 h treatment of MRC5 non-tumorigenic fibroblast 
cell line with Isc Qu did not exhibit marked toxicity even in the concentration range well above MCF7 IC50 value 
(300; 100; 33.3; 11.1 and 3.7 µg/mL) (Fig. 1A, bottom). Furthermore, all concentrations used for MRC5 control 
cell treatment seem to fall well below the IC50 mark (Fig. 1A bottom).
Thus, during 72 h cotreatment experiments with 50 nM Dox, Iscador Qu concentration of 85 µg/mL induced 
the strongest synergistic antitumor activity (Fig. S1A, right table). In addition, Isc Qu concentration of 85 µg/mL 
had no significant impact on MRC5 fibroblast viability (Fig. 1A, bottom) and was therefore selected as a minimal, 
most effective and well tolerated concentration.
MCF7 mono-treatment with 50 nM Dox resulted in an minor increase in subG1 population and cell death 
(Fig. 1B, bottom left and Fig. 1C, right) and massive expansion of G2/M arrested population from 18, 03% in 
untreated (Fig. 1B, top left) to 68, 47% in Dox treated group (Fig. 1B bottom left). Interestingly, cotreatment with 
85 ug/mL Isc Qu abrogated Dox induced G2/M cell cycle block (Fig. 1B, bottom right) accompanied by concom-
itant increase of dying sub-G1 population (Fig. 1B, bottom right). Collectively, our data confirm tumor-selective 
Isc Qu toxicity and reveal that additive antitumor activity of Isc Qu with low-dose Dox occurs by preventing 
G2/M arrest and triggering cell death.
G2/M arrest override during MCF7 cotreatment with Isc Qu and Dox activates intrinsic cell 
death pathway. To gain insight into events underlying Isc Qu mediated switch from senescence to cell 
death of Dox treated MCF7 cells, we asked what type of cell death was prevalent under cotreatment conditions. 
Compared to Dox treated controls, 72 hour cotreatment of MCF7 cells with 85 µg/mL of Isc Qu and 50 nM Dox 
led to strong increase in Annexin V labeled early apoptotic cell population (Fig. 2A), as well as late apoptotic cells 
detectable by double Annexin V and 7AAD staining (Fig. 2A). Consistent with increased early and late apoptotic 
marker positivity (Fig. 2A), cotreatment with Isc Qu and Dox increased the detachment of MCF7 cells (Fig. 1C, 
right) with nearly 100% trypan blue positivity detected among cells in suspension (not shown). Cytotoxic drugs 
have been shown to activate intrinsic/mitochondrial apoptotic pathway69 reflected by measurable changes in 
mitochondrial membrane potential (∆ψm)70, 71, release of cytochrome C, induction and/or activation of proap-
optotic factor Bax and effector caspase372–75. FACS Rh123 fluorochrome incorporation assay76 revealed a dramatic 
loss of mitochondrial membrane potential (Δψm) in MCF7 cells upon 72 hour cotreatment with Isc Qu (Fig. 2B) 
indicating initiation of mitochondrial apoptotic pathway program. Moreover, FACS and qPCR analysis revealed 
a prominent increase of Bax/Bcl-2 ratio during cotreatment with Isc Qu compared to monotreatment conditions 
(Fig. 2C) confirming the activity of the apoptotic program. Thus, synergistic anti-tumor activity observed during 
MCF7 cotreatment with sub-apoptotic concentrations of Dox and Isc Qu is achieved by activation of intrinsic 
apoptotic program.
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Isc Qu cotreatment prevents low-dose Dox induced senescence and SASP in MCF7 cells. Next, 
we sought to address the mechanistic basis underlining Isc Qu mediated switch from Dox induced MCF7 cell 
senescence to apoptosis. Sub-apoptotic doses of chemotherapeutics have been shown to induce cell-cycle arrest 
and senescence both in vitro and in breast cancer patients13, 77–80. Considering that Dox induced G2/M accumu-
lation of MCF7 cells was lost upon co treatment with Isc Qu (Fig. 1B), we next asked whether Isc Qu prevents 
accumulation of senescent tumor cells.
Compared to Dox treated controls, 72 hour cotreatment of MCF7 cells with 85 µg/mL of Iscador Qu and 
50 nM Dox dramatically reduced appearance of senescent cells characterized by flattened morphology with 
enlarged nuclei (Fig. 1C) and SA-ß-Gal-positivity (Fig. S1B). Cancer cell response to genotoxic stress is mediated 
by p53/p21 and p16INK4a/pRB tumor suppressive pathways81–87. Both pathways are complex; each having multi-
ple upstream and downstream regulators and modifying side branches88, 89. Moreover, these pathways were shown 
to cross-regulate each other90–92. Using flow cytometry, immunofluorescence staining and western blot, we next 
measured expression levels of both proteins under treatment conditions described. A significant increase in both 
p21/WAF1 and p53 protein was observed 72 hours after MCF7 Dox treatment (Fig. 3A–C). qPCR data revealed 
that gene expression of both p21 and tp53 has increased under all treatment conditions (Fig. S1C and S1D) but 
resulted in protein stabilization and accumulation only upon Dox treatment (Fig. 3A–C). These results show that 
unlike during Dox treatment, Isc Qu induced p21 promoter activity is independent of p53 likely due to absence 
of efficient DDR pathway activation.
SASP represents a specific program triggered by genotoxic stress in cancer cells25. SASP components may dif-
fer depending on the cell type, tissue type or genomic stressor93. Though efforts are still ongoing to identify SASP 
markers unique for specific cell context, IL-6 and IL-8 are among most prominently detected SASP cytokines 
that seem to be directly controlled by persistent DNA-damage signaling94. Thus, we essayed expression of IL-6 by 
enzyme linked immunosorbent assay (ELISA). 72 h Doxorubicin treatment of MCF7 cells resulted in a ten-fold 
Figure 1. Isc Qu treatment of MCF7 cells abrogates low-dose Dox induced G2/M arrest. (A) MCF7 survival 
plots upon 72 h monotreatment with: Dox (top left), Isc Qu (top right). MRC5 survival plot upon 72 h 
monotreatment with Isc Qu (bottom). (B) Changes in cell cycle phase distribution of MCF7 cells upon 72 h 
treatment with Isc Qu (85 µg/mL), Dox (50 nM) or combination Isc Qu (85 µg/mL) + Dox (50 nM) are shown. 
After treatment, cells were stained with propidium iodide and analyzed by flow cytometry for cell cycle phase 
distribution changes. M1- apoptotic cells with DNA content corresponding to sub-G1 fraction; M2- cells with 
DNA content corresponding to G0/G1 phases; M3- cells with DNA content corresponding to S phase; M4- 
cells with DNA content corresponding to G2/M phases. (C) Light microscope photographs of morphological 
changes of MCF7 cells induced by Dox. Magnification, 10X.
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induction of IL-6 secretion (Fig. 3D) and increased STAT3 activity (Fig. S1E) supporting previously described 
role for IL-6/STAT3 signaling in senescence establishment and SASP maintenance95, 96. Conversely, cotreatment 
with Isc Qu reduced IL-6 secretion (Fig. 3D) and STAT3 activation (Fig. S1E).
Though IL-6 levels detected upon Isc Qu and Dox cotreatment were higher compared to controls (Fig. 3D), 
STAT3 activation seems to be efficiently blocked by Isc Qu and remained significantly lower compared to 
untreated controls (Fig. S1E). Viscum album extracts have been reported to increase tumor infiltration and 
immune system activity97. Among SASP secretome components with potent adverse activity, CCL-2 has been 
recently described as an essential mediator of immune surveillance suppression allowing for tumor progression 
and metastases13, 98, 99. To investigate whether G2 arrested senescent cells produce CCl-2 and if this production 
is affected by Isc Qu cotreatment, we have assayed for CCL2 expression under described treatment conditions 
using FACS. Whereas 72 h Dox treatment of MCF7 cells potently induced CCL-2 protein and mRNA expression, 
addition of Isc Qu strongly abrogated these effects (Fig. 3E). Collectively, our results show that addition of Isc Qu 
to low-dose Dox efficiently blocks senescence from G2/M cell cycle arrested cells and SASP.
Isc Qu induced G2/M senescence switch to apoptosis is accompanied by p38 and Erk1/2 inhi-
bition. One of the well studied mechanisms of Dox toxicity in tumor cells is induction of ROS100. While 
mitochondria can generate damaging ROS101, mitochondrial defects were demonstrated to promote cellu-
lar senescence102–104. Finally, Mistletoe extracts have been reported to have a potent antioxidant activity105–109.
Therefore, we asked whether alterations of ROS levels and corresponding signaling pathways could be responsible 
for the switch from senescence to apoptosis observed during IscQu cotreatment with low-dose Dox.
Figure 2. Cotreatment of MCF7 with Isc Qu and Dox activates intrinsic cell death pathway. (A) Proportion 
of early apoptotic and late apoptotic/necrotic cells was measured by the bivariate Annexin V/7AAD flow 
cytometry after 72 h treatment of MCF7 cells with Isc Qu (85 µg/mL), Dox (50 nM) or combination Isc Qu 
(85 µg/mL) + Dox (50 nM) (top). Bar graph showing results presented as the mean ± SEM of three independent 
experiments (bottom). (B) Dissipation of mitochondrial membrane potential was assessed by flow cytometry 
using rhodamine 123 staining (top). Bar graph showing results presented as the mean ± SEM of three 
independent experiments (bottom). (C) Bax/Bcl-2 ratio levels. Analysis of Bcl-2 and Bax protein(left) and 
mRNA expression (right). Detected mRNA levels were normalized to GAPDH. Results are presented as the 
mean ± SEM of three independent experiments. Asterisks denote statistical significance compared to control 
cells (*p < 0.05; **p < 0.01; ***p < 0.001). Representative dot plots from three independent experiments 
performed in triplicate are shown.
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Data presented in Fig. 4A reveal that all treatment conditions resulted in substantial increase of mitochondrial 
ROS (mROS) production with maximal levels detected in cells undergoing Dox monotreatment. Interestingly, 
total ROS levels did not mimic alterations observed in the mitochondrial compartment though maximum total 
ROS production was also detected upon Dox monotreatmet (Fig. 4A and B). These results suggest that Isc Qu 
likely acts by suppressing ROS generation from other cellular sources such as increased signaling, peroxisome, 
hyperactivation of oxidases, cyclooxygenases, lipoxigenases etc.110.
By increasing production of distinct ROS species111, 112 Doxorubicin was shown to activate Erk1/2 and p38, two 
MAP kinases described to have a central role in establishment of senescence113, 114, SASP induction115 and survival 
upon oxidative injury116, 117. To investigate whether Isc Qu mediates a switch from senescence to apoptosis via 
inhibition of Erk1/2 and p38 MAP kinases, we examined the status of Erk1/2 and p38 by flow cytometry. Increased 
levels of both activated Erk1/2 and p-38 could be readily observed upon 72 h treatment with Dox (Fig. 4C) in 
line with the peak ROS production (Fig. 4A and B). Isc Qu addition almost completely abolished this effect 
reducing both total ROS and activated p38 well below Isc Qu mono-treatment or control levels (Fig. 4B and C, 
respectively). Conclusively, these data suggest that Isc Qu blocks Dox induced ROS production, consequent acti-
vation of Erk1/2 and p38 kinases preventing senescence establishment and SASP.
Discussion
Tumor suppressor function of cellular senescence has been identified in the context of the irreversible cell cycle 
exit118 as well as autocrine and paracrine SASP mediated effects: cell cycle arrest reinforcement119–122 propagation 
Figure 3. Isc Qu cotreatment prevents low-dose Dox induced senescence and SASP in MCF7 cells. Confluent 
MCF7 cells were treated with Isc Qu (85 µg/mL) and Dox (50 nM) alone or in combination for 72 hours and 
were subjected to immunofluorescence, FACS analyses and western blot. Immunofluorescent labeling of (A) 
p21 and (B) p53 protein expression, as well as (C) FACS analysis and immunobloting. Cell nuclei are labeled 
with DAPI (blue). (D) IL-6 protein levels in the supernatant of cultured MCF7 cells upon 72 h treatment with 
Isc Qu (85 µg/mL) and Dox (50 nM) alone or in combination, were measured using an ELISA. IL-6 activity 
was converted to pg according to the manufacturer’s instructions (Affymetrix, eBiosciences, CA, USA). (E) 
Protein expression of CCL-2 in treated MCF7 cells was determined by flow cytometry (left) and presented as 
MFI- the mean fluorescence intensity (right). Results are presented as the mean ± SEM of three independent 
experiments. Asterisks denote statistical significance compared to control cells (***p < 0.001). Representative 
photos and histogram for at least three independent experiments performed in triplicate are shown.
www.nature.com/scientificreports/
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of senescent phenotype on neighboring damaged cells123 and supporting tissue regeneration124–126. Moreover, 
SASP can elicit immune surveillance and clearance of both tumor127–129 and neighboring damaged cells124.
Paradoxically, more recent studies have demonstrated that SASP can promote tumorigenesis by supporting 
proliferation and invasion of surrounding tumor cells21, 23, 130, promoting angiogenesis131 or creating immunosup-
pressive environment allowing for tumor cell escape from immune system recognition and clearance98, 99.
Thus, beneficial and/or detrimental aspects of SASP appear to be critically dependent on the senescence trig-
ger and specific SASP secretome production132.
Our study was designed to identify whether and how Viscum album extracts could potentiate anti-tumor 
activity of sub-apoptotic Doxorubicin concentrations in MCF7 breast cancer cells. In this study we report for 
the first time that VAE potently inhibits chemotherapy induced senescence and triggers apoptosis. We have also 
confirmed previous reports describing selective anti-tumor toxicity of VAE/Isc Qu66. We show that 72 h MCF7 
cell treatment with sub-apoptotic Dox concentrations induces G2/M cell cycle arrest, senescence and SASP which 
were blocked by cotreatment with Isc Qu. The switch from G2/M senescence entry into apoptosis seems to be 
regulated by preventing Dox mediated ROS accumulation and Erk1/2 p38 activation. Our data suggest that G2/M 
cell cycle exit and senescence are regulated by both p53-p21 and p38 activated INK4A/Rb pathway probably 
owing to their extensive crosstalk. A trigger stimulus for Dox induced G2/M senescence seems to be moderate 
ROS production leading to sustained p38 activation114, 133. Persistent p38 activity was shown to induce SASP96, 116  
largely via facilitating NF-kB activation and its recruitment to inflammatory gene promoters such as IL-6 and 
CCL-2134. Previous work has shown that IL-6 plays a key role in oncogene induced senescence establishment25 
and inflammatory secretome maintenance135. Thus, Increased ROS production during Dox treatment would 
likely trigger p38 activity136 establishing a positive feedback loop in IL-6 secretion and secretome maintenance. 
We report that additive antitumor activity of low-dose Dox (50 nM) with Iscador Qu triggers apoptosis while 
reducing ROS, p53 and p21 levels. Our results mimic the findings of Delebinski and colleagues in lauekaemia 
cells137 where mistletoe lectins where shown to suppress p53 and induce TRAIL expression and apoptosis in a 
Figure 4. Isc Qu induced G2/M senescence switch to apoptosis is accompanied by p38 and Erk1/2 inhibition. 
(A) After 72 hour treatment with Isc Qu (85 µg/mL) and Dox (50 nM) alone or in combination, MCF7 cells 
where stained with dyhydrorhodamine 123 for 20 min in order to measurelevels of mitochondrial ROS, or 
(B) incubated 30 min with DCFH-DA to measure total ROS levels. (C) Phosphorylated pErk1/2 and p38 
protein levels were assessed by flow cytometry. MFI-mean fluorescence intensity. Results are presented as 
the mean ± SEM of three independent experiments. Asterisks denote statistical significance compared to 
control cells (*p < 0.05; **p < 0.01; ***p < 0.001). Representative histograms for at least three independent 
experiments performed in triplicate are shown.
www.nature.com/scientificreports/
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dose dependent manner. It is possible that, as previously shown138–140, low-dose-Dox treatment sensitizes MCF7 
cells to Mistletoe lectin-induced TRAIL expression and apoptosis while ROS quenching by the extract attenuates 
p38, Erk1/2, p53 and p21 activation. Considering that we haven’t analyzed temporal profiles of ROS production 
as well as Erk1/2 and p38 activity, it is not clear whether putative cross-talk with TRAIL signaling and resulting 
apoptotic shift takes place at the onset of p38 activation or establishment of the positive feedback loop mediated 
by inflammatory signaling. To our knowledge, this is the first report showing that Viscum Album extract could 
prevent chemotherapy induced senescence by redirecting cells into apoptosis. Further studies elucidating the 
exact timing and molecular mechanism of this “switch” are of special interest both for the therapeutic purposes 
and prevention of ageing-related diseases. In conclusion, our data indicate that Isc Qu can sensitize MCF7 cells to 
apoptotic cell death at senescent concentration of the Dox by down-regulation of ROS, p21/WAF1, and p53 and by 
suppressing SASP profile through prevention of activation of Erk1/2, p38 and STAT3. Therapeutic interventions 
with Isc Qu applied as CAM, whether by dampening the SASP profile or by preventing the therapeutic senescence 
through induction of apoptotic cell death, should be much more effective. Whether Isc Qu is effective in targeting 
endogenously senescent tumor or non-tumorigenic cells remains to be addressed.
Materials and Methods
Drug. Doxorubicin hydrochloride (Sigma-Aldrich, St. Louis, USA) was diluted in sterile water. For the pur-
pose of the study, we used Iscador Qu Spezial (Iscador AG, Switzerland) in 1 mL ampules of 5 mg. This prepara-
tion is fermented aqueous extracts of mistletoe plants growing on oak trees. As confirmed with the manufacturer, 
Iscador Qu Spezial batches used in our experiments are standardized on the basis of their contents of mistletoe 
lectins 391 ± 18.3 ng/mL and viscotoxins 13 ± 3 µg/mL.
Cell line. All cell lines used in this study were obtained from the American Type Culture Collection (Rockville, 
MD) unless specified otherwise. Human breast adenocarcinoma cells (MCF-7) and a single human normal cell 
line (MRC-5) were maintained as monolayer culture in a nutrient medium, MRC-5 cells in the Roswell Park 
Memorial Institute (RPMI) 1640 medium, while MCF7 cells in the DMEM medium. Powdered RPMI 1640 
medium, and DMEM modified medium, were purchased from Sigma Chemicals Co, USA. Nutrient medium 
RPMI 1640 was prepared in sterile deionized water, supplemented with penicillin (192 U/mL), streptomycin 
(200 µg/mL), 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) (25 mM), L-glutamine (3 mM) 
and 10% of heat-inactivated fetal calf serum (FCS) (pH 7.2). Modified DMEM nutrient medium was prepared 
in sterile deionized water, supplemented with penicillin (192 U/mL), streptomycin (200 µg/mL) and 10% of 
heat-inactivated FCS. Cells were grown at 37 °C in 5% CO2 and humidified air atmosphere, by twice weekly 
subculture.
Cytotoxicity assay. Cytotoxic activity of Isc Qu and Dox on MCF7 and MRC5 cells was assessed using 
the MTT assay67, 68. After treatment in 96-well plates, 20 µL of MTT solution (3-(4, 5-dimethylthiazol-2-yl)-2, 
5-dyphenyl tetrazolium bromide) (Sigma-Aldrich, St. Louis, USA) was added to each well. Samples were incu-
bated for 4 h, followed by the addition of 100 μL of 10% SDS and incubated at 37 °C. Absorbance at 570 nm was 
measured the next day.
Cell survival (%) was calculated as an absorbance (A570 nm) ratio between treated and control cells multiplied 
by 100. IC50 was defined as the concentration of the agent that inhibited cell survival by 50% compared to the 
vehicle control.
Flow-cytometric analysis of cell cycle phase distribution. Briefly, 2 × 105 cells/Petri dish (dimensions 
60 × 15 mm, NUNC) were treated with investigated drugs as indicated. After collection, cells were fixed with 
ethanol and stained with propidium iodide (PI) (Sigma-Aldrich, St. Louis, USA)141. Cell cycle phase distribution 
was analyzed by FACS Calibur Becton Dickinson flow cytometer using Cell Quest computer software (Becton 
Dickinson, Heidelberg, Germany)
Apoptotic assay. Apoptotic rates were assessed with flow cytometry using the Annexin V–fluorescein iso-
thiocyanate/and 7AAD (BD Pharmingen, San Diego, CA, USA). Samples were prepared according to manufac-
turer’s instructions. Flow cytometry analysis was performed using a FACS-Calibur cytometer using Cell Quest 
computer software (Becton Dickinson, Heidelberg, Germany).
Quantification of mitochondrial transmembrane potential. Mitochondrial transmembrane poten-
tial (Δψm) was measured using a cationic fluorochrome Rodamine 123 (Rh123) (Sigma-Aldrich, St. Louis, USA) 
as described by Yan et al.76. Briefly, 1 × 106 cells resuspended in 200 μL of phosphate buffered saline were stained 
with Rh123 (2.5 μg/mL) for 30 min at 37 °C. After washing, samples were analyzed by flow cytometry using Cell 
Quest software (Becton Dickinson, Heidelberg, Germany).
Intracellular staining. Cells stained for FACS analysis were treated as described above. For intracellu-
lar staining the following antibodies were used: mouse anti-p21WAF1, clone CP74 (5 µg/mL, Merck Millipore, 
Darmstadt, Germany), mouse anti-Bax, clone 3/Bax (1:100, BD Pharmingen, San Diego, CA, USA), 
FITC-conjugated monoclonal Bcl-2 antibody, clone Bcl-2/100 (1:100, BD Pharmingen, San Diego, CA, USA), 
mouse anti-human Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (1:200, Cell Signaling, Danvers, 
MA, USA), mouse anti-human phospho-p38 MAPK (Thr180/Tyr182) antibody, clone 28B10 (1:800, Cell 
Signaling, Danvers, MA, USA), mouse anti-p53 antibody, clone DO7 (dilution 1:100, Dako, Glostrup, Denmark) 
and mouse anti-p73, clone ER-13 (5 µg/mL, Merck Millipore, Darmstadt, Germany).
Briefly, cells (5 × 105 cells/flask 25 cm2) were allowed to adhere for 24 h in standard conditions, and then 
treated as described in Results. After the stimulation period, cells were fixed the cells immediately by adding 
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pre-warmed Cytofix Buffer for 10 to 12 minutes at 37 °C, and washed twice with PBS containing 1% BSA. After 
permeabilization of the cells using of Perm Buffer for 20 minutes at room temperature and washing, cells were 
incubated with antibodies at room temperature for 60 minutes protected from light, and washed twice with PBS 
containing 1% BSA. After appropriate incubation, cells were washed three times with PBS containing 1% BSA 
and incubated with the corresponding FITC-coupled secondary antibodies (dilution 1:100, BD Pharmingen, 
San Diego, CA, USA). Samples were analyzed on a FACS-Calibur cytometer using Cell Quest software (Becton 
Dickinson, Heidelberg, Germany).
Immunofluorescence Labeling. Cells (5 × 104 cells/cover slip) were allowed to adhere for 24 h in stand-
ard conditions, and then treated as described in Results. Immunofluorescent labeling was performed as previ-
ously described142. Briefly, cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton-X100 (Sigma 
Aldrich), and then immunolabeled with primary antibodies: mouse anti-p21WAF1, clone CP74 (5 µg/mL, Merck 
Millipore, Darmstadt, Germany), mouse anti-p53, clone DO7 (dilution 1:100, Dako, Glostrup, Denmark). 
Samples incubated in 1% BSA in PBS served as negative control. After appropriate incubation (indicated in 
Results), cells were washed three times with PBS and incubated with the corresponding FITC-coupled secondary 
antibodies (dilution 1:100, from Pharmingen) and 1 µg/mL of DAPI (Sigma-Aldrich, St. Louis, USA) for nucleus 
labeling for 1 h at room temperature. Mounted cells were analyzed using an epifluorescent microscope (Olympus, 
Japan).
Analysis of gene expression by Real-time PCR. Total RNA was isolated using TRI REAGENT® BD 
kit (Sigma-Aldrich, St. Louis, USA). cDNA synthesis from total RNA using random primers and MultiScribe™ 
Reverse Transcriptase from High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, CA, USA). 
All target transcripts were detected using TaqMan® Gene Expression Assays Applied Biosystems, CA, USA. All 
reactions were performed in duplicate and the data represent mean ± SEM of three independent experiments. 
Results were analyzed using the classical delta-delta-Ct method. GraphPad Prism 5.04 (GraphPad Software, CA, 
USA) was used to compare means by two way analysis of variance (ANOVA) and Bonferroni method to adjust the 
p-value for multiple comparisons. Differences were considered significant if p < 0.05. P-values for each analysis 
are indicated in Fig. legends.
Senescence associated β-galactosidase staining. Cells (2 × 105 per well) were seeded into 6-well 
plates in DMEM culture medium and after 24 hours treated with investigated drugs for 72 hours. SA-β-gal stain-
ing was performed using Senescence β-galactosidase staining kit (Cell Signaling) according to the manufactures’ 
instructions. Briefly, cells were fixed for 15 min in fixative solution, washed and incubated at 37 °C with X-gal 
(1 mg/mL), dissolved in a solution containing 40 mM citric acid pH 6.5, 5 mM potassium ferrocyanide, 5 mM 
potassium ferricyanide, 150 mM NaCl and 2 mM MgCl2. After 24 h incubation, photographs were taken using a 
standard light microscope (Olympus, Japan).
Enzyme-linked immunosorbent assay. MCF7 cells (5 × 103 per well) were plated in 96-well plates and 
allowed to adhere for 24 h in standard conditions. Upon adherence, cells were treated with investigated drugs for 
72 hours and the culture supernatants were collected. Supernatant concentrations of IL-6, TNF-α and TGF-β 
were measured using ELISA according to manufacturer’s protocols (Affymetrix, eBiosciences, CA, USA).
Measurement of mitochondrial reactive oxygen species. MCF7 mitochondrial reactive oxygen spe-
cies (ROS) levels were measured using a ROS sensitive fluorescent probe, 1, 2, 3 dihydrorhodamine (DHR). 
Fluorescent marker dihydrorhodamine 123 was purchased from Molecular Probes, prepared as a 5 mM stock 
solution in dimethyl sulfoxide, and used at 1 μM. Briefly, cultured MCF7 cells were treated with Isc Qu, Dox and 
their combination with untreated cells maintained as controls. Following 72 h incubation, cells were harvested, 
washed twice, resuspended in 1 μM DHR and incubated at 37 °C for 20 min in the dark. Levels of intracellu-
lar ROS were examined with flow cytometry (FACS Calibur, BD Biosciences, USA). Excitation wavelength was 
485 nm with peak emission measured at 530 nm. Data acquisition and analyses were carried out using Cell Quest 
software (BD Biosciences, USA).
Measurement of total intracellular reactive oxygen species. Generation of reactive oxygen species 
(ROS) in MCF7 cells was measured using a ROS sensitive fluorescent probe, 2,7-dichlorodihydrofluorescein diac-
etate (DCFH-DA). This probe can be oxidized to 2′,7′-dichlorofluorescein (DCF) by ROS and exhibits increased 
green fluorescence intensity. Briefly, cultured MCF7 cells were treated with Isc Qu, Dox and their combination 
with untreated cells maintained as controls. Following 72 h incubation, cells were harvested, washed twice, 
re-suspended in 10 mM DCFH-DA and incubated at 37 °C for 30 min in the dark. Levels of intracellular ROS 
were examined using flow cytometry (FACS Calibur, BD Biosciences, USA). Excitation wavelength used in meas-
urements was 485 nm with peak emission measured at 530 nm. Data acquisition and analyses were carried out 
using Cell Quest software (BD Biosciences, USA).
Western blot analysis. Following 72 h treatment, protein samples extracted from MCF7 cells were used 
for immunoblot assay. Cells were washed twice with ice-cold PBS, and lysed in Cell Lysis Buffer (20 mM Tris 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 
b-glycerolphosphate, 1 mM Na3PO4, 1 mg/mL Leupeptin, 1 mM PMSF). Cell lysates were centrifuged then nor-
malized by the Lowry assay; proteins in lysates were separated by sodium dodecyl sulfate (SDS)- polyacryla-
maide gel electrophoresis (PAGE). Proteins were transferred to nitrocellulose membranes and membranes were 
blocked with TBST containing 5% non-fat milk. Following overnight incubation of membranes with primary 
antibodies at 4 °C, membranes were washed with TBST containing 0.1% Tween 20, and incubated with goat 
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antimouse peroxidase- conjugated secondary antibodies for 60 min at room temperature. Blots were probed with 
an enhanced chemiluminescence (ECL) substrate (Pierce, Thermo scientific) and exposed to Hyperfilm ECL to 
visualize the immunoreactive bands.
Statistical analysis. Data are presented as mean standard deviation (SEM) of three independent experi-
ments. Comparisons between two groups were performed using Student’s t-test. p-value 0.05 was considered to 
be significant.
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